Friday 25 February 2022

 INTIMATION FOR BODHIKA SEMINAR - 28/2/2022

DEPARTMENT OF PANCHAKARMA
GOVT. AYURVEDA COLLEGE, THIRUVANANTHAPURAM


NAME  OF  FIRST PRESENTEE : DR  SWETHA E J
   
THESIS TOPIC: TO COMPARE THE EFFECT OF 
THRIPHALA  UDWARTHANA  AND THRIPHALA
 UTSADANA IN OBESITY

NAME OF GUIDE: DR T K SUJAN

DATE: 28/02/2022

TIME: 2:00-4:00 PM

VENUE: MICROSOFT TEAMS

ABSTRACT

Overweight and Obesity are defined as an abnormal fat accumulation that may impair health. Obesity is expressed in terms of body mass index (BMI). WHO says a person with BMI of 30 or more is said to be obese and is a major risk factor for a number of chronic diseases.

 In Ayurveda it can be considered as Sthoulya. According to Charaka Acharya, Udwarthana is one among the treatment modalities of sthoulya. Udwarthana is kaphamedo vilayana, stireekarana of angas and twak prasadanam. Udwarthana is classified into two by acharya Susrutha with relation to mode of application as Udgharshana and Utsadana. Utsadana gives lovely apperance for the females, praharsha, soubagya,mrija and laghutwa. Thriphala is Rasayana , it cure skin diseases and also have kaphamedohara property. Objective of this study is to compare the efficacy of these two treatments in obesity.

Patients of both sexes aged 25-65, with obesity attending OPD and IPD of Govt. Ayurveda College Panchakarma Hospital, Poojappura are randomly selected as study population. They are divided into two groups namely group A and group B. Then group A is subjected to Udwarthana for 14 days and group B is subjected to Utsadana for 14 days. Both the groups were assessed before and after the treatment(ie.0th ,15th, 21st,28th day) with regards to changes in BMI, waist circumference, bodyweight, waist to hip ratio and skin fold thickness.Data will be analyzed according to statistical test.

Wednesday 16 February 2022

 INTIMATION FOR BODHIKA SEMINAR - 21/2/2022


DEPARTMENT OF KAYACHIKITSA

GOVT. AYURVEDA COLLEGE, THIRUVANANTHAPURAM

NAME  OF  FIRST PRESENTEE : DR SOUMYA R 
   
THESIS TOPIC: EFFECT OF GOKSHURADI 
GIUGGULU IN MICROALBUMINURIA  ASSOCIATED WITH TYPE 2 DIABETES MELLITUS
 

NAME OF GUIDE: DR ASWATHY S  MD (Ay)

DATE: 21/02/2022

TIME: 2:00-4:00 PM

VENUE: MICROSOFT TEAMS

ABSTRACT

Microalbuminuria (MAU) is defined as levels of albumin ranging from 30-299 mg in a 24-h urine collection and is an important predictor of Diabetic Nephropathy. Diabetes Mellitus has become an ever-growing world-wide health problem in all socio-economic groups. India currently represents 49 percent of the world’s diabetes burden, with an estimated 72 million cases in 2017, a figure expected to almost double to 134 million by 2025. The increasing incidence of the disease elevates its complications ranging from acute, life-threatening conditions such as severe hypoglycemia or ketoacidosis to chronic, debilitating complications affecting multiple organ systems such as retinopathy, nephropathy, neuropathy and cardiovascular disease. Out of these, Diabetic Nephropathy (DN) occuring due to microangiopathies is definitely on a rise. The earliest clinical evidence of Diabetic Nephropathy is Microalbuminuria (MAU) as defined as 30-299 mg/d in a 24 –hour collection. Since MAU is the prime marker for early suspection to renal affliction, the need of studies with regard to reducing MAU and maintaining glycemic control becomes important.

The drug of study is Gokshuradi Guggulu mentioned in YogaratnakaraMehaadhikara, indicated in conditions of prameha, vataroga, vatasonita, mutraghata, mutradosha and pradara.  In addition, the ingredients are primarily found to be pramehahara and rasayana with special affinity to vasti and mutravahasrotas. The study is intended to evaluate the effect of the drug in reducing microalbuminuria associated with Type 2 DM. The trial drug is administered in a dose of 2 gutikas of 500 mg each thrice a day, half an hour before food with lukewarm water for a period of 30 days. A sample size of 23 patients aged between 35 to 65 years with known Type 2 Diabetes Mellitus and urine albumin within the range of 30-299 mg in 24-hr urine sample are selected according to inclusion and exclusion criteria. Level of urine microalbumin in 24-hr urine sample is noted before the study and after one month on the 31st day. The data collected will be statistically analysed.



Friday 11 February 2022

 INTIMATION FOR BODHIKA SEMINAR - 14/2/2022

DEPARTMENT OF KAUMARA BHRITYA

GOVT. AYURVEDA COLLEGE, THIRUVANANTHAPURAM

NAME  OF  FIRST PRESENTEE :DR KEERTHANA RAMDAS
   
THESIS TOPIC:EFFECT OF TIKTAKA GRITHA AND 
YASHTICHURNA IN THEORY OF MIND AMONG CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER OF THE AGE GROUP 5-12 YEARS

NAME OF GUIDE: DR Anil Kumar.M.V M.D(Ay) M.D(Ay)

DATE: 14/02/2022

TIME: 2:00-4:00 PM

VENUE: MICROSOFT TEAMS

                                                                  ABSTRACT

Attention Deficit Hyperactivity Disorder is the most commonly diagnosed childhood disorder, characterized by extreme and persistent restlessness, sustained and prolonged motor activity, difficulties in sustaining attention and impulsivity. The present study aims to analyse combined effect of Tiktaka gritha and Yashtichurna in children with Attention Deficit Hyperactivity Disorder and to find out the improvement in Theory of Mind among them. The cases will be recorded using socio-demographic and clinical data sheet.   Children’s hyperactivity/inattention measured using ADHDT-2 scale and Theory of Mind will be assessed using Theory of Mind task battery. To evaluate the effect of Tiktaka gritha and Yashtimadhu churna in ADHD and Theory of Mind, a sample of 12 children with age group of 5–12 years fulfilling the inclusion criteria and diagnostic criteria will be selected from Government Ayurveda hospital for women and children Poojapura OPD.  Trial drug will be given for sixty days. Before and after treatment, data will be collected, scored and statistically analysed using appropriate statistical technique.

Saturday 5 February 2022

INTIMATION FOR BODHIKA SEMINAR - 7/2/2022


DEPARTMENT OF DRAVYA GUNA VIJNANAM

GOVT. AYURVEDA COLLEGE, THIRUVANANTHAPURAM


NAME  OF  FIRST PRESENTEE :DR APARNA S G                                                       

THESIS TOPIC: IN VITRO AND IN VIVO WOUND HEALING ACTIVITY OF Cosmostigma racemosum (Roxb) Wight (vaattuvalli) LEAVES

NAME OF GUIDE: DR A SHAHUL HAMEED

DATE: 07/02/2022

TIME: 2:00-4:00 PM

VENUE: MICROSOFT TEAMS

ABSTRACT

Cosmostigma racemosum(Roxb.)Wight is a green milky weed climber belonging to Asclepiadaceae family. The present study is conducted to evaluate the wound healing activity of the plant. The descriptions from Hortus Malabaricus and various ethnobotanical studies of the sacred groves of temples in Kannur district serve as the base of this study. Wound healing is a complex process, which involves haemostasis, inflammation, proliferation and remodelling with scar tissue formation. The mobilization and proliferation of fibroblasts and angiogenesis play a major role in wound healing. A potent wound healer aids the body tissues in these steps more effectively by reducing the healing time .

The pharmacognostical, physical and phytochemical analysis of Cosmostigma racemosum(Roxb.) Wight are done as these details are not yet scientifically validated. In the in vitro assay, the cell mobilization of fibroblasts will be monitored by Scratch assay of L929 cells. Angiogenetic potential of the drug will be assessed using CAM Assay model (Chick Chorioallantropic membrane model). The wound healing activity of the plant is studied in vivo in Wistar rats by Excision wound model. Excision wounds of approximately 450mm2 will be made on the dorsal side of pre anesthetised rats. Three groups containing six rats each are used for study. For group I topical serveas the negative control.For group II application of Povidone iodine is used which serve as the standard. For Group III topical application of leaf paste of Cosmostigma racemosum (Roxb.)Wight is used which serve as the test group. The application is once daily for 14 days. Assessment will be done on 0th , 2nd ,4th ,6th ,8th ,10th and 14th days. The rate of wound contraction, period of epithelisation and histopathological analysis are assessed by this model.